Lilly Adds Dual-Acting Insomnia Compound With Acquisition Of Hypnion
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal will add the Phase II compound HY10275 to Lilly’s existing insomnia candidate pruvanserin.
You may also be interested in...
Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.
Merck Serono Extends CNS Collaboration With Newron, Invests In Israel
Merck Serono's revised deal with Newron gives the latter a license to develop two additional compounds, with Merck holding a buy-back option.
Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries
It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.